Q-omics provides the consensus-scored SMARCC2 profile across patient tissues and cancer cell-line models. SMARCC2 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in UCS. Among the 18 cancer types available for tumor–normal comparison, SMARCC2 is differentially expressed in 13, with the highest sampling consensus in COAD. Additionally, SMARCC2 protein abundance shows 25,173 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight UCS, COAD, and GBM as cancer lineages where SMARCC2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SMARCC2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SMARCC2 survival associations across molecular data types. SMARCC2 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (4) and mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SMARCC2 RNA expression–survival associations across cancer types. High SMARCC2 expression shows unfavorable associations in LUSC and BLCA, but favorable associations in UCS, KIRC, SCLC and LGG. The UCS Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .003). Together, the overview and detailed table identify UCS as the clearest survival context for SMARCC2 RNA expression.
This table summarizes SMARCC2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 7. The strongest signals are observed in COAD for RNA and COAD for protein.
This table ranks reproducible tumor–normal expression differences for SMARCC2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SMARCC2 shows higher tumor expression in COAD, LIHC, BLCA, HNSC, STAD and CHOL. The COAD box plot shows higher SMARCC2 RNA expression in tumor versus normal tissue (log2 FC = +0.296, t-test p = .002).
This table shows molecular features associated with SMARCC2 in patient tissues and cancer cell lines. In patient samples, SMARCC2 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, SMARCC2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_NSCLC_LUAD, while CRISPR and shRNA rows add functional-dependency signals in SOFT_TISSUE and BLOOD_Leukemia.
